ProQR Therapeutics (PRQR) Receivables (2022 - 2025)

ProQR Therapeutics (PRQR) has disclosed Receivables for 3 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 69.1% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2025, up 69.1% year-over-year, with the annual reading at $8.3 million for FY2025, 69.1% up from the prior year.
  • Receivables hit $8.3 million in Q4 2025 for ProQR Therapeutics, up from $4.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $57.8 million in Q4 2022 to a low of $4.9 million in Q4 2024.
  • Historically, Receivables has averaged $23.7 million across 3 years, with a median of $8.3 million in 2025.
  • Biggest YoY gain for Receivables was 69.1% in 2025; the steepest drop was 69.1% in 2025.
  • Year by year, Receivables stood at $57.8 million in 2022, then plummeted by 91.53% to $4.9 million in 2024, then surged by 69.1% to $8.3 million in 2025.
  • Business Quant data shows Receivables for PRQR at $8.3 million in Q4 2025, $4.9 million in Q4 2024, and $57.8 million in Q4 2022.